Table 4 Association between HIF-1α expression and breast cancer recurrence by quintile of recurrence time and ER/TAM group among 1682 subjects from the ProBe CaRe population-based case control study
Time to recurrence | Median time to recurrence (yaers) | ER+/TAM+ breast cancer patients | ER−/TAM− breast cancer patients | ||
|---|---|---|---|---|---|
Cases/controls | Adjusted OR (95% CI)a | Cases/controls | Adjusted OR 95% CI)a | ||
1 to < 2 | 1.5 | 109/113 | 1.03 (0.54, 1.96) | 113/105 | 0.73 (0.42, 1.27) |
2 to < 3 | 2.4 | 80/85 | 1.16 (0.55, 2.44) | 67/72 | 0.74 (0.36, 1.54) |
3 to < 4 | 3.4 | 88/78 | 3.41 (1.28, 9.06) | 32/33 | 2.50 (0.81, 7.68) |
4 to < 6 | 4.7 | 113/115 | 0.79 (0.41, 1.52) | 27/27 | 0.76 (0.22, 2.60) |
6–10 | 7.3 | 68/73 | 1.39 (0.59, 3.30) | 19/17 | 5.78 (0.61, 55.0) |